|
1
|
Biazzo A and De Paolis M:
Multidisciplinary approach to osteosarcoma. Acta Orthop Belg.
82:690–698. 2016.PubMed/NCBI
|
|
2
|
Biermann JS, Chow W, Reed DR, Lucas D,
Adkins DR, Agulnik M, Benjamin RS, Brigman B, Budd GT, Curry WT, et
al: NCCN guidelines insights: Bone cancer, version 2.2017. J Natl
Compr Canc Netw. 15:155–167. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nataraj V, Batra A, Rastogi S, Khan SA,
Sharma MC, Vishnubhatla S and Bakhshi S: Developing a prognostic
model for patients with localized osteosarcoma treated with uniform
chemotherapy protocol without high dose methotrexate: A
single-center experience of 237 patients. J Surg Oncol.
112:662–668. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boye K, Del Prever AB, Eriksson M, Saeter
G, Tienghi A, Lindholm P, Fagioli F, Skjeldal S, Ferrari S and Hall
KS: High-dose chemotherapy with stem cell rescue in the primary
treatment of metastatic and pelvic osteosarcoma: Final results of
the ISG/SSG II study. Pediatr Blood Cancer. 61:840–845. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Heaton TE, Hammond WJ, Farber BA, Pallos
V, Meyers PA, Chou AJ, Price AP and LaQuaglia MP: A 20-year
retrospective analysis of CT-based pre-operative identification of
pulmonary metastases in patients with osteosarcoma: A single-center
review. J Pediatr Surg. 52:115–119. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oki H, Kaneko MK, Ogasawara S, Tsujimoto
Y, Liu X, Sugawara M, Takakubo Y, Takagi M and Kato Y:
Characterization of monoclonal antibody LpMab-7 recognizing
Non-PLAG domain of podoplanin. Monoclon Antib Immunodiagn
Immunother. 34:174–180. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kunita A, Kashima TG, Ohazama A,
Grigoriadis AE and Fukayama M: Podoplanin is regulated by AP-1 and
promotes platelet aggregation and cell migration in osteosarcoma.
Am J Pathol. 179:1041–1049. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kato Y, Kaneko MK, Kuno A, Uchiyama N,
Amano K, Chiba Y, Hasegawa Y, Hirabayashi J, Narimatsu H, Mishima K
and Osawa M: Inhibition of tumor cell-induced platelet aggregation
using a novel anti-podoplanin antibody reacting with its
platelet-aggregation-stimulating domain. Biochem Biophys Res
Commun. 349:1301–1307. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miyata K, Takemoto A, Okumura S, Nishio M
and Fujita N: Podoplanin enhances lung cancer cell growth in vivo
by inducing platelet aggregation. Sci Rep. 7:40592017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takagi S, Sato S, Oh-hara T, Takami M,
Koike S, Mishima Y, Hatake K and Fujita N: Platelets promote tumor
growth and metastasis via direct interaction between
Aggrus/podoplanin and CLEC-2. PLoS One. 8:e736092013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Swain N, Kumar SV, Routray S, Pathak J and
Patel S: Podoplanin-a novel marker in oral carcinogenesis. Tumour
Biol. 35:8407–8413. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamaki E, Yajima T, Kosaka T, Mogi A,
Tanaka S and Kuwano H: Podoplanin overexpression in human
mesothelioma cell lines enhances the tumorigenic phenotype. Oncol
Rep. 29:932–940. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaneko MK, Oki H, Ogasawara S, Takagi M
and Kato Y: Anti-podoplanin monoclonal antibody LpMab-7 detects
metastatic lesions of osteosarcoma. Monoclon Antib Immunodiagn
Immunother. 34:154–161. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
DePaolo CJ, Foster WS, Dabezies EJ and
D'Ambrosia RD: A case report of malignant mesenchymoma with
discussion of musculoskeletal tumor staging: The Enneking system.
Orthopedics. 11:1263–1276. 1988.PubMed/NCBI
|
|
15
|
Jo VY and Doyle LA: Refinements in sarcoma
classification in the current 2013 world health organization
classification of tumours of soft tissue and bone. Surg Oncol Clin
N Am. 25:621–643. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Grimer RJ, Aydin BK, Wafa H, Carter SR,
Jeys L, Abudu A and Parry M: Very long-term outcomes after
endoprosthetic replacement for malignant tumours of bone. Bone
Joint J. 98-B:857–864. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Koirala P, Roth ME, Gill J, Chinai JM,
Ewart MR, Piperdi S, Geller DS, Hoang BH, Fatakhova YV, Ghorpade M,
et al: HHLA2, a member of the B7 family, is expressed in human
osteosarcoma and is associated with metastases and worse survival.
Sci Rep. 6:311542016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Puri A, Byregowda S, Gulia A, Crasto S and
Chinaswamy G: A study of 853 high grade osteosarcomas from a single
institution-Are outcomes in Indian patients different? J Surg
Oncol. 117:299–306. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Angelini A, Ceci F, Castellucci P,
Graziani T, Polverari G, Trovarelli G, Palmerini E, Ferrari S,
Fanti S and Ruggieri P: The role of 18F-FDG PET/CT in
the detection of osteosarcoma recurrence. Eur J Nucl Med Mol
Imaging. 44:1712–1720. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kadota K, Huang CL, Liu D, Nakashima N,
Yokomise H, Ueno M and Haba R: The clinical significance of the
tumor cell D2-40 immunoreactivity in non-small cell lung cancer.
Lung Cancer. 70:88–93. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yuan P, Temam S, El-Naggar A, Zhou X, Liu
DD, Lee JJ and Mao L: Overexpression of podoplanin in oral cancer
and its association with poor clinical outcome. Cancer.
107:563–569. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Minardi D, d'Anzeo G, Lucarini G, Filosa
A, Zizzi A, Simonetti O, Polito M Jr, Offidani AM, Di Primio R,
Montironi R and Muzzonigro G: D2-40 immunoreactivity in penile
squamous cell carcinoma: A marker of aggressiveness. Hum Pathol.
42:1596–1602. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakazawa Y, Takagi S, Sato S, Oh-hara T,
Koike S, Takami M, Arai H and Fujita N: Prevention of hematogenous
metastasis by neutralizing mice and its chimeric
anti-Aggrus/podoplanin antibodies. Cancer Sci. 102:2051–2057. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Martin-Villar E, Megias D, Castel S,
Yurrita MM, Vilaró S and Quintanilla M: Podoplanin binds ERM
proteins to activate RhoA and promote epithelial-mesenchymal
transition. J Cell Sci. 119:4541–4553. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wicki A, Lehembre F, Wick N, Hantusch B,
Kerjaschki D and Christofori G: Tumor invasion in the absence of
epithelial-mesenchymal transition: Podoplanin-mediated remodeling
of the actin cytoskeleton. Cancer Cell. 9:261–272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kunita A, Kashima TG, Morishita Y,
Fukayama M, Kato Y, Tsuruo T and Fujita N: The platelet
aggregation-inducing factor aggrus/podoplanin promotes pulmonary
metastasis. Am J Pathol. 170:1337–1347. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Suzuki-Inoue K, Kato Y, Inoue O, Kaneko
MK, Mishima K, Yatomi Y, Yamazaki Y, Narimatsu H and Ozaki Y:
Involvement of the snake toxin receptor CLEC-2, in
podoplanin-mediated platelet activation, by cancer cells. J Biol
Chem. 282:25993–26001. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nakazawa Y, Sato S, Naito M, Kato Y,
Mishima K, Arai H, Tsuruo T and Fujita N: Tetraspanin family member
CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and
suppresses pulmonary metastasis. Blood. 112:1730–1739. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cueni LN, Hegyi I, Shin JW, Albinger-Hegyi
A, Gruber S, Kunstfeld R, Moch H and Detmar M: Tumor
lymphangiogenesis and metastasis to lymph nodes induced by cancer
cell expression of podoplanin. Am J Pathol. 177:1004–1016. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Han J, Yong B, Luo C, Tan P, Peng T and
Shen J: High serum alkaline phosphatase cooperating with MMP-9
predicts metastasis and poor prognosis in patients with primary
osteosarcoma in Southern China. World J Surg Oncol. 10:372012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim SH, Shin KH, Moon SH, Jang J, Kim HS,
Suh JS and Yang WI: Reassessment of alkaline phosphatase as serum
tumor marker with high specificity in osteosarcoma. Cancer Med.
6:1311–1322. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Marais LC, Bertie J, Rodseth R, Sartorius
B and Ferreira N: Pre-treatment serum lactate dehydrogenase and
alkaline phosphatase as predictors of metastases in extremity
osteosarcoma. J Bone Oncol. 4:80–84. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hao H, Chen L, Huang D, Ge J, Qiu Y and
Hao L: Meta-analysis of alkaline phosphatase and prognosis for
osteosarcoma. Eur J Cancer Care (Engl). 26:2017. View Article : Google Scholar
|
|
35
|
Nagano A, Ishimaru D, Nishimoto Y, Akiyama
H and Kawai A: Primary bone sarcomas in patients over 40 years of
age: A retrospective study using data from the bone tumor registry
of Japan. J Orthop Sci. 22:749–754. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lisenda L, Linda ZA, Snyman FPJ, Kyte RD
and Lukhele M: Osteosarcoma patient outcomes at a South African
tertiary hospital. S Afr Med J. 107:754–757. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang B, Pang QJ, Zhang HJ and Yuan Y:
Multivariate analysis for prognostic factors among 43 patients with
osteosarcoma. Zhongguo Gu Shang. 24:982–986. 2011.(In Chinese).
PubMed/NCBI
|
